The Stop TB Partnership is convening the first ever global meeting of TB patients and key affected populations on 2nd and 3rd - 5th November in Bangkok, Thailand.

The Challenge Facility for Civil Society provides grants to technically sound and innovative interventions to support the engagement of communities in national tuberculosis responses.

01 September, Sydney, Australia - Parliamentarians from the Asia Pacific formed the Asia Pacific TB Caucus today, at an historic meeting in Sydney, Australia, to drive progress against this intractable disease. This is the first parliamentary network of its type in the region.

In contrast to the recent US cycloserine price increase, the Global Drug Facility slashed the price of cycloserine by 55% earlier this year compared to the previous year.

04 September 2015 - Buenos Aires, Argentina - The fourth and final regional consultation on the Global Plan to Stop TB 2016-2020 ended this week as over 40 participants came together representing the diverse partners and stakeholders from the Latin America and Caribbean region.

The survey can be found here. You are invited to take the survey by September 1, 2015.

The European region has special challenges to face: high MDR and XDR-TB rates, lengthy hospital stays, and the need for changes in health, human rights policies including decriminalization, real civil society and community engagement.

Despite the critical need for increased TB resources, donor funding for TB decreased by nearly 10% in 2014.

The Stop TB Partnership's Global Drug Facility now has a special communications channel dedicated to Procurement & Supply Management issues.

25 June 2015 - In March 2015, Médecins Sans Frontières (MSF), ACTION Global Health Advocacy Partnership, SWIFT Response Project, Treatment Action Campaign (TAC), Treatment Action Group (TAG) and 84 other organisations issued a call to action urging global health actors and the TB community to form a consortium with the objective of meeting time-bound, concrete targets for scaling up use of new drugs in DR-TB treatment.